Launch of breast cancer vaccine trials
Ohio: Preliminary trials of the first breast cancer vaccine of its kind have begun at the Cleveland Clinic in the United States.
The first phase of these medical trials (Phase One Clinical Trials) will recruit 24 women who were diagnosed at an early stage with cancer called ‘triple negative breast cancer’ but after treatment they also recovered from breast cancer. Were done.
Triple-negative breast cancer is a dangerous type of breast cancer that, once treated, often strikes again and is fatal for 25% of patients over the next five years.
About 12 to 15 percent of women with breast cancer develop this type of cancer, the majority of whom are African-American women. In addition, the cancer is more common in women with a specific type of genetic modification (BRCA-1).
One dose of the vaccine should be given every two weeks to women volunteers participating in medical trials.
The first dose will be 10 micrograms, the second 100 micrograms and the third dose 1000 micrograms. The purpose of this strategy is to determine the minimum effective dose of the vaccine and the maximum dose that the human body can tolerate.
These medical trials will last for a year and will end in September 2022.
If these tests yield positive results, then second- and third-stage medical tests will be performed, possibly for another five to six years.
So, if all goes well, this breast cancer vaccine could be available by 2030.
Meta will introduce four new VR headsets in the next two years California: Founder of…
Factors to consider while choosing a sports betting site Online gambling has become famous among…